Meet Dr. Diana Roettger and IAG’s Oncology Experts at ESMO, 2019
With novel #cancer treatments, especially with the development of immune system activating drugs (immune-oncology), we are seeing acute demand for the integration of advanced imaging and specific quantitative biomarkers for the accurate assessment of patient response to treatment and understanding of such complex concepts as #pseudo-progression, tumor #micro-environment and #targeted therapies.
The tumour size assessment in the early phase oncology trials is increasingly relying on the use of use objective quantitative information from the advanced image sequences (DCE, DSC, DWI) in addition to standard criteria such as RECIST or iRECIST, in order to decide if the patient should remain on the treatment.
This is one of the hottest topics in clinical research. IAG expert team and collaborators will be attending ESMO’19 , 27 September – 1 October 2019, in Barcelona, Spain on the latest innovations and new data from the trials powered with our proprietry machine learning and AI methodologies.
IAG, Image Analysis Group, maximizes chances for bio-pharmaceutical companies to succeed in taking break-through therapies from phase I to the patient by bringing our robust and efficient cloud technology platform DYNAMIKA, Artificial Intelligence (AI) and Machine Learning (ML) driven data analytics and proprietary imaging biomarkers to enable faster fact-based decisions, optimized workflows and control over the study conduct and financial risks.
ESMO is the leading European professional organisation for medical oncology. Comprising 18,000 oncology professionals from over 150 countries, we are the society of reference for oncology education and information. The meeting is a multi-professional platform for oncology education and exchange, and for immense international visibility for scientific research, this year the Congress also features a dedicated nursing track through a collaboration with the European Oncology Nursing Society (EONS).